Equity Overview
Price & Market Data
Price: $3.28
Daily Change: -$0.04 / 1.22%
Daily Range: $3.26 - $3.35
Market Cap: $379,307,488
Daily Volume: 249,446
Performance Metrics
1 Week: 1.54%
1 Month: -13.19%
3 Months: -27.53%
6 Months: -27.21%
1 Year: 240.3%
YTD: -17.34%
Company Details
Employees: 32
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.